Corbus Pharmaceuticals
CRBP
99 hedge funds and large institutions have $129M invested in Corbus Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 34 increasing their positions, 22 reducing their positions, and 26 closing their positions.
747% more call options, than puts
Call options by funds: $6.57M | Put options by funds: $776K
55% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 22
7% less funds holding
Funds holding: 107 → 99 (-8)
7.77% less ownership
Funds ownership: 97.69% → 89.92% (-7.8%)
19% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 26
47% less capital invested
Capital invested by funds: $243M → $129M (-$114M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.76M |
| 2 |
O
OrbiMed
New York
|
+$4.36M |
| 3 |
AC
Armistice Capital
New York
|
+$3.96M |
| 4 |
ACM
Altium Capital Management
New York
|
+$3.19M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$2.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$6.15M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$5.99M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$4.56M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.91M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.96M |
CRBP Hedge Fund Activity: Q4 2024 in Review
99 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q4 2024, worth a combined $129M — down 47% from $243M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of CRBP and 21 opened new positions — a net loss of 5 holders — while 22 trimmed existing stakes and 34 added.
The largest buyer was Millennium Management, adding an estimated $4.76M. The largest seller was State Street, cutting an estimated $6.15M.
- 99 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q4 2024, down from 107 in Q3 2024.
- Funds reported $129M of Corbus Pharmaceuticals stock for Q4 2024, down 47% quarter-over-quarter.
- 21 funds opened new Corbus Pharmaceuticals positions in Q4 2024 and 26 closed out, a net change of -5 holders.
- The largest Corbus Pharmaceuticals buyer in Q4 2024 was Millennium Management, an estimated $4.76M added.
- The largest Corbus Pharmaceuticals seller in Q4 2024 was State Street, an estimated $6.15M sold.
Based on aggregated 13F filings for Q4 2024.